Navigation Links
TransMessenger Transfection Reagent Handbook

s 2 g. A pipetting scheme for optimizing the transfection of adherent cells in 6-well plates is provided in Table 2, page 11. For transfection using other culture formats, please refer to Table 3

Amount of Enhancer R
The RNA (g) to Enhancer R (l) ratio of 1:2 given in the pipetting scheme on page 11 should not be changed. Efficient condensation of RNA with Enhancer R is determined by the mass quantity of RNA.

Ratio of TransMessenger Transfection Reagent to RNAEnhancer R mixture
The overall charge of the TransMessengerRNA complex is determined by the ratio of TransMessenger Transfection Reagent to RNAEnhancer R mixture. Optimal binding of TransMessengerRNA complexes to negatively charged groups (e.g., sialylated glycoproteins) on the cell surface requires a slightly positive net charge. The ratio of TransMessenger Transfection Reagent (l) to RNA (g) is an important factor to optimize for every new cell type and RNA used. As a starting point for optimization we recommend using an RNA:TransMessenger Transfection Reagent ratio of 2 g RNA to 8 l TransMessenger Reagent when using 6-well plates. A pipetting scheme for optimizing the transfection of adherent cells in 6-well plates is provided in Table 2. To optimize transfection in other culture formats, prepare separate transfection mixtures using:
The starting point RNA and TransMessenger Transfection Reagent quantities listed in Table 3,
Roughly half the listed ratios and quantities
Double the listed ratios and quantities.

Incubation period with TransMessengerRNA complexes
Remove TransMessengerRNA complexes 3 hours after their
'"/>

Source:


Page: All 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

Related biology technology :

1. TransMessenger Transfection Reagent
2. Efficient DNA transfection of primary CNS neurons using TransMessenger Transfection Reagent
3. TransMessenger Transfection Reagent
4. Efficient RNAi-mediated gene silencing in neuronal cells using QIAGEN siRNA and TransMessenger Transfection Reagent*
5. Highest Transfection Efficiency of an Endotoxin-Sensitive Mammalian Cell Line
6. Optimizing Transfection Conditions for Studying Signal Transduction Pathways
7. Transfection of Green Fluorescent Protein into Human Adrenalcarcinoma Cells
8. Improve Lipid- or Calcium Phosphate-Mediated Transfection of Human Dermal Fibroblasts
9. Versatile Transfection Reagent Offers Low Toxicity and Consistent Performance
10. Low-Toxicity, Lipid-Mediated Transfection of Mammalian Cells
11. Mycoplasma Contamination Reduces the Effect of Lipid-Mediated Transfection of Mammalian Cells
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: TransMessenger Transfection Reagent Handbook

(Date:3/6/2015)... 2015 Global Specimen Solutions, Inc. ... on specimen management and informatics, announced today that ... Solutions, Inc. is excited to catapult our growing ... will further enhance our proprietary informatics tools and ... research. GSS has proved rapid market uptake of ...
(Date:3/6/2015)... March 6, 2015 BioSpecifics Technologies Corp. (NASDAQ: ... in class collagenase-based products marketed as XIAFLEX ® ... XIAPEX ®  in the EU, announced today that it ... at 8:30 a.m. ET on Friday, March 13, 2015 ... financial results and provide a corporate update. ...
(Date:3/6/2015)... 2015   Senomyx , Inc. (NASDAQ: ... technologies to discover, develop, and commercialize novel flavor ingredients ... John Poyhonen , the Company,s President and Chief ... President and Chief Financial Officer, will present an overview ... March 11, at 2:00 p.m. Eastern Time (11:00 a.m. ...
(Date:3/6/2015)... (PRWEB) March 06, 2015 Transparency Market Research ... and Other Crops - Global Industry Analysis, Size, Share, Growth, ... the global isoxaflutole market was valued at US$ 116.3 Mn ... by 2020, expanding at a CAGR of 5.1% from 2014 ... isoxaflutole stood at 2,569.5 kilo tons in 2013. , Isoxaflutole ...
Breaking Biology Technology:Global Specimen Solutions, Inc. Closes Series A Funding 2Global Specimen Solutions, Inc. Closes Series A Funding 3BioSpecifics Technologies Corp. to Host Conference Call to Report Fourth Quarter and Full Year 2014 Financial Results on Friday, March 13, 2015 2SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE THE 27TH ANNUAL ROTH CONFERENCE 2Isoxaflutole Market is Expected to Reach US$ 163.0 Mn by 2020 : Transparency Market Research 2Isoxaflutole Market is Expected to Reach US$ 163.0 Mn by 2020 : Transparency Market Research 3
... DCGN ) today announced its consolidated financial results ... conference call to discuss the,year,s results and operating highlights ... EDT/12 noon GMT (details below)., Net loss for ... to $85.5 million for the full year 2006. Basic ...
... JOSE, Calif., March 12 Oncolys BioPharma,Inc. (Tokyo, ... USA),announced today that they have entered into a ... throughout Asia, Tacere,s,RNA interference (RNAi)-based Hepatitis C virus ... agreement resulted from the,strategic alliance entered into by ...
... WILMINGTON, Del., March 12 AstraZeneca (NYSE:,AZN) announced ... two,pivotal Phase III studies for vandetanib, the company,s ... of,non-small cell lung cancer (NSCLC). The two studies ... cell lung Cancer) and ZEAL (ZACTIMA,Efficacy with Alimta ...
Cached Biology Technology:deCODE Genetics Announces Full-year 2007 Financial Results 2deCODE Genetics Announces Full-year 2007 Financial Results 3deCODE Genetics Announces Full-year 2007 Financial Results 4deCODE Genetics Announces Full-year 2007 Financial Results 5deCODE Genetics Announces Full-year 2007 Financial Results 6deCODE Genetics Announces Full-year 2007 Financial Results 7deCODE Genetics Announces Full-year 2007 Financial Results 8deCODE Genetics Announces Full-year 2007 Financial Results 9Oncolys BioPharma and Tacere Therapeutics Sign Strategic Alliance and License Agreement to Develop and Commercialize RNAi Hepatitis C Drug 2Oncolys BioPharma and Tacere Therapeutics Sign Strategic Alliance and License Agreement to Develop and Commercialize RNAi Hepatitis C Drug 3AstraZeneca Completes Enrollment in Two Pivotal Phase III Studies of the Investigational Drug Vandetanib (ZACTIMA(R)) in Non-Small Cell Lung Cancer (NSCLC) 2AstraZeneca Completes Enrollment in Two Pivotal Phase III Studies of the Investigational Drug Vandetanib (ZACTIMA(R)) in Non-Small Cell Lung Cancer (NSCLC) 3
(Date:3/5/2015)... 5, 2015 In Brazil , ... already using these solutions and 42 percent planning to invest ... approximately 25 percent of the companies will be investing in ... majority of companies in the region are currently opting for ... model will command significant attention in the coming years. This ...
(Date:3/4/2015)... 04, 2015 Research and Markets ... the "Global Biometrics Market Forecast and Opportunities, ... The market for biometric authentication systems is projected ... till 2020 The driving forces for ... needs, government projects and constant development in technology. ...
(Date:3/3/2015)... 3, 2015 Cryoport, Inc. (OTCBB: ... cryogenic logistics solutions for the life sciences ... cell lines, clinical research organizations, vaccine manufacturers, ... the expansion of its relationship with ... Hutch") Clinical Research Division with the inclusion ...
Breaking Biology News(10 mins):Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 4Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3
... East Asia is where the wolf was tamed and became the ... But now researchers at the Royal Institute of Technology (KTH) in ... "For the first time in world history it is possible to ... in time, and how many wolves were tamed," says Peter Savolainen, ...
... and other aquatic fauna in recent centuries are not restricted ... that species in rivers and lakes worldwide also experienced sharp ... is frequently overlooked by natural resource managers, according to an ... , Authors Paul Humphries and Kirk Winemiller argue that as ...
... Three out of ten women who undergo polar body ... of polar body analysis (PBA) is described by researchers in ... edition of Deutsches rtzeblatt International , in which they ... Int 2009; 106(33): 533-8). Polar bodies are by-products of ...
Cached Biology News:Shifting baselines confound river restoration 2New developments in reproductive medicine 2
... antibody raised against a partial recombinant MAK. ... ~ 457 a.a) partial recombinant protein with GST ... Accession: BC039825 ... OMIM: 154235, GeneID: ...
...
Mouse polyclonal antibody raised against a partial recombinant DDEF2. NCBI Entrez Gene ID = 8853...
Mouse monoclonal antibody raised against a full length recombinant SCGB3A2. NCBI Entrez Gene ID = SCGB3A2...
Biology Products: